AGM Statement

RNS Number : 7469P

Faron Pharmaceuticals Oy

31 May 2018

 

Faron Pharmaceuticals Ltd

("Faron" or the "Company")

AGM Statement

TURKU - FINLAND, 31 May 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the clinical stage biopharmaceutical company, will hold its Annual General Meeting ("AGM") at 11am (Finnish time) in the BioCity building, Mauno Conference Center, address Tykistökatu 6, 20520 Turku, Finland.

At the meeting, Dr Markku Jalkanen, Chief Executive Officer, will make a presentation to shareholders attending. No new information will be disclosed. The presentation will shortly be available at https://www.faron.com/investors.

The Company continues to assess and analyse the data from the Phase III INTEREST trial of Traumakine in the treatment of ARDS and will provide an update to the market in due course.

For more information please contact:

Faron Pharmaceuticals Ltd

Dr Markku Jalkanen, Chief Executive Officer

[e-mail] 

Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Matthew Neal, Lindsey Neville

Phone: [phone]

E-mail: [e-mail]

Westwicke Partners, IR (US)

Chris Brinzey

Phone: [phone]

E-Mail: [e-mail]

Panmure Gordon (UK) Limited, Nomad and Broker

Freddy Crossley, Emma Earl, Ryan McCarthy

Phone: [phone]

About Faron Pharmaceuticals Ltd

Faron (AIM:FARN) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy. The Company's lead candidate Traumakine, to prevent vascular leakage and organ failures, has completed a Phase III clinical trial in Acute Respiratory Distress Syndrome (ARDS). An additional European Phase II Traumakine trial is underway for the Rupture of Abdominal Aorta Aneurysm ("RAAA"). Faron's second candidate Clevegen is a ground breaking pre-clinical anti-Clever-1 antibody. Clevegen has the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients. Faron is based in Turku, Finland. Further information is available at www.faron.com

 

END

 

 

NRAEAKSEDFNPEFF